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Impaired organ perfusion in severe falciparummalaria arises frommicrovascular sequestration of parasitized cells and endothe-
lial dysfunction. Endothelial dysfunction in malaria is secondary to impaired nitric oxide (NO) bioavailability, in part due to
decreased plasma concentrations of L-arginine, the substrate for endothelial cell NO synthase. We quantified the time course of
the effects of adjunctive L-arginine treatment on endothelial function in 73 patients with moderately severe falciparummalaria
derived from previous studies. Three groups of 10 different patients received 3 g, 6 g, or 12 g of L-arginine as a half-hour infusion.
The remaining 43 received saline placebo. A pharmacokinetic-pharmacodynamic (PKPD)model was developed to describe the
time course of changes in exhaled NO concentrations and reactive hyperemia-peripheral arterial tonometry (RH-PAT) index
values describing endothelial function and then used to explore optimal dosing regimens for L-arginine. A PKmodel describing
arginine concentrations in patients with moderately severe malaria was extended with two pharmacodynamic biomeasures, the
intermediary biochemical step (NO production) and endothelial function (RH-PAT index). A linear model described the rela-
tionship between arginine concentrations and exhaled NO. NO concentrations were linearly related to RH-PAT index. Simula-
tions of dosing schedules using this PKPDmodel predicted that the time within therapeutic range would increase with increas-
ing arginine dose. However, simulations demonstrated that regimens of continuous infusion over longer periods would prolong
the time within the therapeutic range evenmore. The optimal dosing regimen for L-arginine is likely to be administration sched-
ule dependent. Further studies are necessary to characterize the effects of such continuous infusions of L-arginine on NO and
microvascular reactivity in severe malaria.
The majority of severe malaria cases and deaths are caused byPlasmodium falciparum (1, 2). While mortality has been re-
duced with wider use of the rapidly parasiticidal drug artesunate
(3), and with improved supportive care, mortality from severe
falciparum malaria remains 8 to 15% (4–7). Adjunctive therapies
targeting the underlying pathogenic processes may reduce mor-
tality further (8).
Impairment of organ perfusion arising from microvascular se-
questration of parasitized red cells and endothelial dysfunction is
central to the pathophysiology of severe falciparum malaria (9–
12). Both adults and children with severe falciparum malaria have
impaired bioavailability of nitric oxide (NO) (11, 13) and reduced
plasma concentrations of L-arginine (11, 14), a semiessential
amino acid and substrate for endothelial cell NO synthase. Im-
paired NO bioavailability is associated with endothelial activation
(11), impaired endothelial function (11), impaired perfusion, and
mortality (15) in severe malaria. Agents that increase NO bioavail-
ability, such as L-arginine, inhaled NO, or NO donors, have been
proposed as potential adjunctive treatments to improve endothe-
lial function and microvascular perfusion in severe malaria. For
patients with moderately severe malaria, comparable hypoargin-
inemia has been described (11), although endothelial dysfunction
is not as profound as in patients with severe malaria (16).
In a previous study with adults with moderately severe falcip-
arum malaria, we described the natural time course of the recov-
ery of plasma L-arginine concentrations and endothelial function
(16). In addition, a nonrandomized trial evaluated the changes in
L-arginine concentration by intervention with ascending-dose ar-
ginine infusions (17). We found that endothelial dysfunction in
moderately severe malaria (5) is L-arginine reversible and that
adjunctive L-arginine treatment was safe (18) and able to improve
NO bioavailability (11). Although artesunate is very rapidly para-
siticidal (7), it has not been able to reduce the case fatality in the
first 48 h in adult severe malaria. It is possible, within the first 2
days when the arginine and NO concentrations are significantly
reduced, that administration of L-arginine might be beneficial in
improving microvascular function and organ perfusion in these
patients.
In the current study, this existing pharmacokinetic (PK) model
of L-arginine (17) was expanded to include two important phar-
macodynamic (PD) biomeasures, exhaled NO concentrations and
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the reactive hyperemia-peripheral arterial tonometry (RH-PAT)
index, a validated measure of endothelial function (19, 20). The
aim of this study was to quantify the time course of the effects of
L-arginine adjunctive therapy on measures of endothelial function
in patients with moderately severe malaria and to explore doses
and dosing schedules of adjunctive L-arginine that would increase
RH-PAT significantly and thus guide dosing regimens for inter-
vention studies in severe malaria.
MATERIALS AND METHODS
Data. Patient data were available from two previous studies and are de-
scribed elsewhere (11, 16, 17). Briefly, these studies included an observa-
tional study that addressed the natural history of arginine recovery involv-
ing 48 patients with moderately severe falciparum malaria (16) and a
nonrandomized trial with another 30 patients (17). Overall, 78 adult pa-
tients with moderately severe falciparum malaria were included. They
were patients at the Mitra Masyarakat Hospital in Timika, Papua, Indo-
nesia. Thirty patients were included in an intervention arm receiving L-
arginine, and 48 patients were in an observational group receiving a sim-
ilar volume of saline to study the natural history of arginine recovery.
Patient characteristics for both groups were not significantly different
(Table 1). In the intervention arm, 3 g, 6 g, or 12 g of L-arginine was
administered as a half-hour infusion to three groups of 10 patients.
Plasma arginine concentrations were measured before and at the end of
the infusion and at approximately 5, 20, 30, and 60 min and 2, 4, 8, 24, and
48 h after arginine administration. In addition, exhaled NO concentra-
tions were measured before and approximately 0.5, 1, 1.5, 2, 3, 5, 20, and
48 h postdose. After the treatment, patients were monitored for 72 h or
until well enough to be discharged. During this follow-up, the RH-PAT
index (19, 20) was determined at approximately 1, 3, 20, and 48 h postdose
and before discharge. Patients without pharmacodynamic data (i.e., NO
and RH-PAT) were excluded from the pharmacokinetic-pharmacody-
namic (PKPD) analysis, leaving 73 patients available for analysis.
Assays for arginine, nitric oxide, andRH-PAT index. (i)Determina-
tion of plasma concentrations of L-arginine. Venous blood was collected
from patients and within 30 min after collection, plasma was separated by
centrifugation and stored at 70°C until analysis. Amino acids were ex-
tracted from a plasma sample of 50 l and mixed with an internal stan-
dard (50 l of norleucine) and 200 l of cold ethanol. Deproteinized
plasma was derivatized with AccQFluor reagent (Waters Corp., Milford,
MA), and amino acids were measured by high-performance liquid chro-
matography (Shimadzu, Kyoto, Japan) as described by Wang et al. (21).
The assay was validated, and the linear range was quantified at 12.01 to
384.24 M. The limit of detection and limit of quantification were 3.71
and 11.24 M, respectively.
(ii) Determination of nitric oxide concentration in breath. Breath
samples were analyzed with an NO analyzer (NIOX; Aerocrine AB, Solna,
Sweden) using American Thoracic Society guidelines (22). The exhaled
NO concentration (in parts per billion) was measured at a flow rate of 250
ml per second (11).
(iii) Determination of RH-PAT index. Reactive hyperemia-periph-
eral arterial tonometry (RH-PAT; Itamar Medical, Caesarea, Israel) is a
validated noninvasive NO-dependent measure method of measuring en-
dothelial function (19, 20). After a 20-min equilibration time, RH was
induced by a 5-min occlusion of the arm. Changes in pulse wave ampli-
tude before and after occlusion of the arm were measured by finger
probes. The RH-PAT index was calculated by dividing the PAT scores
during RH by the initial PAT scores (19).
Model development. (i) Population (PK)model. Data were analyzed
using the nonlinear mixed effect modeling software NONMEM version
7.2 and Wings for NONMEM (WFN). The first-order conditional estima-
tion (FOCE) method with interaction was used to fit models to the data.
Yeo et al. previously developed a two-compartment PK model describing
L-arginine concentrations over time in patients with moderate severe ma-
laria. This model accounted for endogenous L-arginine concentrations
(17). It was built on data for 78 patients, with 73 arising from this data set.
Parameters have been reestimated with the new data set, and different
residual error models were evaluated. This evaluation was based on good-
ness-of-fit criteria such as measurement of objective function (equivalent
to minus twice the log likelihood), parameter estimates, between-subject
variability, and graphical diagnostics, including goodness-of-fit plots and
individual predictions overlaid with the data.
(ii) PKPDmodel:NO.The PK model was used to drive a PD model for
nitric oxide (NO). A combined model was developed in NONMEM to
link the population PK model with the exhaled nitric oxide concentra-
tions in both patient groups (saline and L-arginine group). The PD model
was fitted via the sequential population PK parameters and data (PPPD)
method by conditioning the PK parameters (23). NO models were based
on arginine as a precursor. Initially, given the very short half-life of NO
(only seconds [24]), models that incorporated an immediate link between
arginine and NO concentration were considered. Three assumptions were
required to relate exhaled NO concentrations to plasma arginine concen-
trations. (i) The equilibrium for intracellular and extracellular arginine is
reached faster than arginine clearance. Under this assumption, the cellular
steady state is reached rapidly and arginine disposition is the rate-limiting
step, rather than the arginine transport into the cell. Therefore, plasma
arginine concentrations will proportionally represent the intracellular ar-
ginine concentrations and can be used directly. (ii) The equilibrium for
NO in exhaled air and airway and alveolar epithelial cells is reached faster
than NO clearance from the lungs. Therefore, the NO concentration in
exhaled air is proportional to the concentration in airway and alveolar
epithelial cells, and exhaled concentrations indirectly represent epithelial
NO concentrations. (iii) Lung epithelial cell NO concentrations parallel
endothelial cell NO concentrations. Deviation from these assumptions
would be seen if there is a delay in the time to maximum (Tmax) plasma
arginine concentration versus the Tmax exhaled NO.
(iii) PKPD model: endothelial function. The population PKPD
model was then expanded to incorporate RH-PAT index, an NO-depen-
dent measure of endothelial function (19). Initially, RH-PAT was directly
linked to plasma arginine concentration. Finally, models were considered
that were based on the likely pathophysiology of malaria that links L-ar-
ginine administration via the intermediary biochemical steps (NO pro-
duction) to endothelial function (RH-PAT index). The links between
RH-PAT and NO were tested to be related in a linear, log linear, or a
maximum-effect (Emax) model.
Model evaluation. Models were evaluated by goodness-of-fit plots
and visual predictive checks (VPCs) (25, 26). Graphics were created in
MATLAB (MathWorks; version 7.13, release R2011b) and the Xpose4
package in R (R platform, version 3.0.3). For VPCs, the 10th, 50th (me-
dian), and 90th percentiles of the observed and simulated NO concentra-
tions and RH-PAT index values were plotted against time after the study
began. In addition, the 95% confidence intervals around the simulated
percentiles were constructed.
Dose simulations. The final PKPD model was used to describe and
predict the expected beneficial effect of L-arginine for the treatment of
malaria. Deterministic simulations were performed using MATLAB to
identify suitable dosing regimens for L-arginine resulting in increased ex-
haled NO concentrations and improved measurements of the RH-PAT
TABLE 1 Patient characteristics
Characteristic
L-Arginine
infusion group
Saline infusion
group All subjects
No. of patients 30 43 73
No. (%) of males 20 (67) 28 (65) 48 (66)
No. (%) of Papuans 24 (80) 39 (90) 63 (86)
Weight (kg)a 57.5 (43–77) 57 (42–73) 57 (42–77)
Age (yrs)a 24.5 (18–54) 28 (18–56) 27 (18–56)
a Values for this parameter are medians, with ranges in parentheses.
PKPD Model of Arginine in Malaria
January 2016 Volume 60 Number 1 aac.asm.org 199Antimicrobial Agents and Chemotherapy
 o
n
 Septem
ber 20, 2016 by W
ALAEUS LIBRARY/BIN 299
http://aac.asm
.org/
D
ow
nloaded from
 
index. Improvement in RH-PAT (a measure of endothelial function) was
used as a surrogate endpoint for clinically relevant improvement in organ
perfusion in comparing different dosages and dosing schedules to deter-
mine the best dosing regimen. The therapeutic range, a range of RH-PAT
measurements believed to represent an improvement in overall microvas-
cular function and organ perfusion, was defined as an RH-PAT index
above the population mean found after 48 h of antimalarial treatment in
the control arm in those patients that recovered completely. This value
occurs at a time when there has been significant clinical and microvascular
recovery (16). The percentage of time in the therapeutic range was calcu-
lated for each dose regimen to find the optimal dosing schedule.
RESULTS
Data. A total of 73 patients were enrolled, 43 in the observational
group and 30 in the group receiving L-arginine. For the observa-
tional group, the natural time course of the recovery of L-arginine
concentrations during malaria treatment is shown in Fig. 1. In the
intervention arm, arginine concentrations are the sum of pre-
dicted endogenous arginine and infused arginine. In Fig. 2a to d,
arginine concentrations are shown over time and an increase in
concentration is seen over the observation period in the placebo
group. For the same patients, exhaled NO concentrations are
shown in Fig. 2e to h. Baseline concentrations of NO are highly
variable. In the group receiving the highest dose of arginine, an
increase in NO concentrations was seen just after time zero (Fig.
2h). For each patient, the RH-PAT index was determined at mul-
tiple time points (Fig. 2i to l), with increasing RH-PAT values
indicating recovery of endothelial function. Again, high variability
was seen, but with evidence of higher peak values of RH-PAT with
the higher dose groups.
Population (PK)model. Yeo et al. described arginine in a two-
compartment model with arginine baseline concentrations and
intravenous dosing (17). This model was tested with the modified
FIG 1 Arginine recovery over time during 2 days of antimalarial treatment.
Arginine concentrations from subjects in the control arm (n 43) are plotted
against time after start of treatment.
FIG 2 Arginine concentrations (a to d), exhaled nitric oxide concentrations (e to h), and RH-PAT index values (i to l) against time for subjects in different dose
groups: those receiving no arginine (a, e, and i), a dose of 3 g (b, f, and j), a dose of 6 g (c, g, and k), or a dose of 12 g (d, h, and l). The dose or saline was administered
at time zero. Arginine concentrations are plotted on a semilog scale. Nitric oxide was measured by breath analysis. RH-PAT index values are the results from
measurements with an EndoPAT device.
Brussee et al.
200 aac.asm.org January 2016 Volume 60 Number 1Antimicrobial Agents and Chemotherapy
 o
n
 Septem
ber 20, 2016 by W
ALAEUS LIBRARY/BIN 299
http://aac.asm
.org/
D
ow
nloaded from
 
data set, in which 5 people were excluded due to no PD measure-
ments. The structural model was found to be stable and parame-
ters were reestimated (Table 2). An empirical second-order poly-
nomial was used to describe natural recovery of arginine as per the
previously published model (17). The model improved signifi-
cantly (drop in objective function value of 28 points; P  0.05)
when variability was used to describe the differences between in-
dividuals, rather than baseline alone (as per reference 17). The
model was then defined as per equation 1:
BLArg (t) (Arg0  t1 t t2 t
2) exp (1) (1)
where BLArg(t) is the baseline value of arginine concentration at
time t, t was indexed to a time set at 2 days prior to presentation
(approximately the start of symptoms), Arg0 is the average base-
line value of arginine in the population (at time zero), and t1 and
t2 are the coefficients in the polynomial linking arginine recovery
to time. The between-subject differences (1) were described by a
log normal distribution with variance (). A visual predictive
check (VPC) was performed to evaluate the model (Fig. 3).
PDmodel for nitric oxide.The final population PK model was
linked with the exhaled NO concentrations in both patient groups
(saline and L-arginine groups). The best model was a linear model
(equation 2):
NOi,j (BLNO,i SLNO  (E[Argi,j] BLArg,i)) exp1i,j
 2i,j (2)
where NOi,j is the jth predicted exhaled nitric oxide concentration
for the ith subject, BLNO,i the ith patient’s baseline value of NO (at
time zero), SLNO the slope to describe the linear relationship be-
tween arginine concentrations and NO concentrations, E[Argi,j]
the expectation of plasma arginine concentration for the jth observa-
tion of the ith subject, and BLArg,i the estimated baseline arginine
concentration for the ith subject. The model includes between-sub-
ject variability for Argi,j and BLNO,i, which describe the variability of
the individual parameters around the population mean values. Also,
a combined (proportional [ε1i,j] and additive[ε2i,j]) error model is
included to account for the residual unexplained variability (RUV) in
NO. Using this model, the decrease in objective function value was
significant (P 0.05), and to evaluate the model, a visual predictive
check was performed (Fig. 3).
PD model for endothelial function. The population PKPD
TABLE 2 Parameter estimates for the population PK model
Parameter Value
SE (%
RSE)l Bootstrapm
Exogenous L-arginine
CLi CL	 (WTi/60)
k1 	 f
CL (liters/h)a 30.3 15.4 28.9
k1 (allometric constant
for CL)
2.47 21.9 2.45
f (fractional effect of
Papuan ethnicity
on CL)
1.9 16.9 2.1
V1i V1	 (WTi/60)
k2
V1 (liters)b 26.6 12 26.4
k2 (allometric constant
for V1)
0.757 70.4 0.69
V2 (liters)c 80.1 27.5 90.3
Q (liters/h)d 22 18.6 22.8
CL (% CV)e 33.9 14.2 31.0
V1 (% CV)f 19.5 54.5 24.6
Endogenous L-arginine
Arg0 (mg/liter)
g 6.07 5.7 6.03
t1 (mg/liter/h)
h 0.0365 50.4 0.0533
t2 (mg/liter/h
2)i 0.0000348 53.4 0.0000871
Arg0 (% CV)
j 44.5 17.8 43.1
Residual error

add (mg/liter)
k 0 FIX 0

prop (% CV)
k 28.6 20.5 27.0
a CL, clearance; CLi, clearance of the ith subject, WTi, body weight of the ith subject.
b V1, volume of distribution in the central compartment.
c V2, volume of distribution in the peripheral compartment.
d Q, intercompartmental clearance.
e CL, between-subject variance for clearance in the central compartment (percent
coefficient of variation [CV]).
f V1, between-subject variance for volume of distribution in the central compartment
(percent CV).
g Arg0, population mean of initial baseline arginine concentration.
h t1, first-order coefficient of the polynomial to describe arginine recovery after P.
falciparum infection.
i t2, second-order coefficient of the polynomial to describe arginine recovery after
infection.
j BLArg, between-subject variance for arginine baseline concentration over time.
k 
add and 
prop, standard deviation of the additive and proportional components of
the residual error, respectively.
l RSE, relative standard error (%).
m Bootstrap was performed with 1,000 samples.
FIG 3 Visual predictive checks of arginine concentrations (left), nitric oxide concentrations (middle), and RH-PAT (right) over time. Observed data (circles)
and the median (solid line) and 10th and 90th percentiles (dashed lines) for simulated data with 95% confidence intervals (shaded areas) are shown.
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model was expanded to incorporate the RH-PAT index, a marker
for endothelial function. RH-PAT was directly linked to plasma
arginine concentration, but this model was not stable. Linking the
RH-PAT data to NO concentration improved the stability and
predictive performance of the model. The decrease in the objec-
tive function values for both a linear and an Emax model were
significant (P  0.05). However, parameter estimates were more
plausible in the linear model than in theEmax model, and the linear
model (equation 3) was more stable:
EFi,j (BLEF,i SLEF  (E[NOi,j] BLNO,i)) exp (3i,j)
 4i,j (3)
where EFi,j (endothelial function) is the predicted value of the
RH-PAT index describing endothelial function for the jth obser-
vation of the ith subject, BLEF,i the ith patients’ initial value of
RH-PAT (at time zero), SLEF the slope to describe the linear
relation between NO and RH-PAT, E[NOi,j] the expected value
of exhaled NO concentration (from equation 2, evaluated at
ε1 ε2 0), and BLNO,i the estimated baseline value of NO (at
time zero). The model includes between-subject variability for
NOi,j and BLEF,i. Also, a combined (proportional and additive)
error model is included to account for the RUV in RH-PAT (ε3i,j
and ε4i,j, respectively). Parameter estimates of the complete PD
model are shown in Table 3. Furthermore, another VPC was per-
formed to evaluate the model (Fig. 3).
Dosing simulations. The final PKPD model, linking L-argi-
nine administration via NO production to endothelial function,
was used to perform deterministic dose simulations. The lower
limit of the therapeutic range was defined as the mean of RH-PAT
index found in the patients in the saline group after 48 h of anti-
malarial treatment (1.87), and there was no upper limit to the
range other than that provided by normal hyperemia. The 48-h
time point was chosen because by this time there is significant
microvascular and clinical recovery (16). A standard virtual sub-
ject (with a weight of 60 kg and of Papuan descent) was dosed with
one of the following dosage regimens: (i) 3, 6, 12, or 30 g over 0.5
h or (ii) 12 g by continuous infusion over 0.5, 4, 12, 24, and 48 h.
Each regimen was assessed for the percentage of time in the ther-
apeutic range (above the base value of RH-PAT of 1.87). Increas-
ing doses led to increased time percentage, with 14.8, 25.6, 36.2,
and 50.5% for the 3-, 6-, 12-, and 30-g doses over 30 min, respec-
tively (Fig. 4). With increasing infusion duration, the percentages
of time that therapeutic RH-PAT values occurred over the 48-h
period after start of the infusion were 36.2, 40.5, 51.8, 71.5, and
TABLE 3 PD parameter estimates for final PKPD model
Parameter Value SE (% RSE)i Bootstrapj
PD model, nitric oxide
BLNO (ppb)
a 18.2 7.5 18.2
SLNO
b 0.0243 56.8 0.0281
BLNO (% CV)
c 59.1 8.7 58.8
Residual error (NO)

add (ppb)
d 0 FIX 0

prop (% CV)
d 35.5 22.7 35.4
PD model, RH-PAT
BLEF
e 1.86 1.9 1.89
SLEF
f 0.145 73.1 0.190
RH-PAT(0) (% CV)g 12.5 12.4 12.2
Residual error (RH-PAT)

add
h 0 FIX 0

prop (% CV)
h 21.3 10.0 21.3
a BLNO, baseline nitric oxide concentration prior to treatment.
b SLNO, slope to describe linear relation arginine plasma concentration with NO.
c BLNO, between-subject variance for baseline nitric oxide concentration.
d 
add and 
prop, standard deviation of the additive and proportional components of
the residual error for nitric oxide, respectively.
e BLEF, baseline measurement of RH-PAT index prior to treatment.
f SLEF, slope to describe linear relation NO with RH-PAT.
g BLEF, between-subject variance for baseline RH-PAT measurement.
h 
add and 
prop, standard deviation of the additive and proportional components of
the residual error for RH-PAT, respectively.
i RSE, relative standard error (%).
j Bootstrap was performed with 1,000 samples.
FIG 4 Percentage of time above the therapeutic target for different dosages. The therapeutic target was defined as an RH-PAT score of 1.87. Each dose was
administered as a 0.5-h infusion.
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98.9% for infusion durations of 0.5, 4, 12, 24, and 48 h of a 12-g
dose, respectively, and 50.5, 54.9, 66.3, 86.7, and 99.6% for a 30-g
dose (Fig. 5).
DISCUSSION
Previous work (27, 28) has formulated a link between L-arginine
administration and endothelial function. In their work, Bode-
Böger et al. describe a strong correlation between plasma arginine
concentrations and its vascular effects in healthy human subjects
(28). This is the first work to quantify the time course of the rela-
tionship, using a PKPD model between L-arginine administration
to endothelial function in acute clinical illness. L-Arginine is a
known substrate for endothelial cell nitric oxide synthase, and
intravenous administration of arginine has been shown to im-
prove endothelial function in moderately severe falciparum ma-
laria (11). In this study, data from 73 patients with malaria from
previous projects (11, 16, 17) were used to develop a PKPD model
that links L-arginine administration via NO production as the in-
termediary biochemical step to endothelial function (RH-PAT in-
dex). Visual predictive checks indicated that the final model was
able to describe arginine concentrations in plasma, NO concen-
trations in breath, and RH-PAT measurements adequately.
Yeo et al. described the pharmacokinetics of a single-dose
L-arginine infusion in adult patients with moderately severe
malaria in a two-compartment model with a second-order
polynomial for the natural time course of the recovery of L-ar-
ginine (17). Since the polynomial function is an empirical de-
scription of the change in arginine baseline concentrations
over time, it should not be used to predict arginine concentra-
tions that occur48 h postadmission. This earlier study found
that exogenous L-arginine had a shorter half-life in patients
with malaria than in healthy individuals. Arginine metabolism
is known to be compartmentalized within the body, which
causes the plasma arginine concentration to be only indirectly
in balance with intracellular arginine metabolism (29). Within
endothelial cells, the arginine concentration is high enough to
saturate endothelial NO synthase, but when exogenous argi-
nine is introduced, NO production still increases, the so-called
“arginine paradox” (30). Therefore, in patients with decreased
NO production, such as patients with falciparum malaria, ad-
ministration of arginine could be expected to increase NO pro-
duction instantly.
The endothelial NO production in vivo is dependent on the
intracellular movement of extracellular L-arginine by cationic
amino acid transporters (CAT-1 and CAT-2) (31). When pa-
tients received exogenous arginine, the exhaled NO concentra-
tions increased without any apparent delay. Our assumption
that the equilibrium for intracellular and extracellular arginine
is rapid was therefore supported by the data. Under this as-
sumption, the cellular steady state is reached rapidly and argi-
nine disposition is rate-limiting, rather than the arginine trans-
port into the cell. Therefore, plasma arginine concentrations
will proportionally represent the arginine concentrations avail-
able for NO production and can be used directly. The model
was used to perform deterministic dose simulations to study
the effect of adjunctive arginine treatment on the RH-PAT in-
dex. RH-PAT index, a measure of endothelial function, was
used as a surrogate measure of organ perfusion and the thera-
peutic range was used as biomarker for the improvement in
organ perfusion. The percent time achieving therapeutic re-
sponse increased with increasing arginine dose, but simula-
tions demonstrated that regimens of continuous infusion over
longer periods might prolong the therapeutic response even
more. Because of the short half-life of NO, elevated NO con-
centrations would be maintained only for the duration of in-
creased arginine concentrations. Therefore, reversal of endo-
thelial dysfunction in patients with falciparum malaria would
be expected only for the duration that arginine concentrations
remain elevated. We expect, therefore, that in administering
L-arginine to the eventual target group, patients with severe
malaria, continuous infusions of L-arginine will also be re-
quired. The safety of 8-h infusion of 12 g of L-arginine has now
been demonstrated in a small pilot study with adults with se-
vere malaria (32); however, the volume of distribution and
FIG 5 Increasing infusion durations for a 12-g dose of arginine. (A) The black dashed line represents no arginine dose, the black solid line a 0.5-h infusion, the
dotted line a 4-h infusion, the dashed dotted line a 12-h infusion, the gray dashed line a 24-h infusion, and the gray solid line a 48-h infusion. (B) Percentage of
time above the therapeutic target for different dosing schedules for a 12-g dose of arginine (solid line) and a 30-g dose of arginine (dashed line).
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clearance of L-arginine appeared to be greater in severe malaria
than in moderately severe malaria. Trials of larger doses than
used in this pilot study will be needed, again as a continuous
infusion. Randomized clinical trials of continuous infusions of
higher doses of L-arginine in severe malaria are in progress
(ACTRN12612000571875).
Since the variability in NO concentrations and RH-PAT is very
high, it may be hard to predict the concentration effects of L-argi-
nine for each individual patient, and further research is needed to
determine potential causes of variability among patients. Now
that variability has been quantified, it is possible that patient char-
acteristics or other biomarkers influencing NO bioavailability and
severity of microvascular dysfunction (33, 34) could potentially be
used to individualize the dose.
The study had several limitations. We note that exhaled NO
may not reflect the time course of endothelial NO exposure and
has not been useful as a marker of vascular endothelial function
in some settings (35–37). In this work, we assumed that exhaled
NO was a marker of epithelial NO production and that this
would parallel the time course of endothelial exposure. While
this assumption has not been specifically tested, the model does
not provide evidence against this measure of the time course of
NO exposure. It remains clear that the relationship between
plasma L-arginine concentrations is highly variable. In addi-
tion, although it is estimated that at least 50% of reactive hy-
peremia peripheral arterial tonometry (RH-PAT [19]) re-
sponse is dependent on endothelial NO production (11, 38),
other mechanisms for endothelial dysfunction could not be
excluded. While there have been recent concerns regarding the
suitability of RH-PAT to assess endothelial function in early-
phase clinical pharmacology studies (39), its utility in acute
systemic inflammation has been demonstrated (11, 40). To
evaluate endothelial function, we assumed that RH-PAT is a
good indicator of vascular reactivity for which there is good
evidence (19).
In conclusion, the time course of effects of L-arginine ad-
junctive therapy on NO production and endothelial function
in patients with moderately severe falciparum malaria was
quantified. The developed PKPD model was used for simula-
tions of dosing schedules and predicted that the percentage of
time of normalized RH-PAT might increase with increased in-
fusion duration, indicating strong schedule dependence. Fur-
ther work is necessary to characterize the effects of these regi-
mens on NO and vascular reactivity in patients with severe
malaria.
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